Biomaterials for cancer immunotherapy

Kinan Alhallak, Jennifer Sun, Barbara Muz, Abdel Kareem Azab

Research output: Chapter in Book/Report/Conference proceedingChapter

4 Scopus citations


Cancer immunotherapy has advanced significantly in recent years due to its promising clinical outcomes in a variety of cancer malignancies and holds great promise in becoming the “cure” for cancer. Cancer immunotherapy is the treatment that stimulates a person’s own immune system to recognize, target, and eliminate cancer cells. As the field progresses with emerging and novel strategies, the ability to manipulate the immune system while mitigating toxicities becomes the hurdle for clinical translation. To control for both efficacy and safety, biomaterials have been incorporated into immunotherapies to achieve tissue- and/or cell-specific immunomodulation, overcome immunosuppression, and address tumor microenvironment heterogeneity. This chapter reviews different immune-based treatment modalities and how biomaterials (such as polymer scaffolds, nanoparticles, and engineered cells) are used to improve upon these major strategies. This chapter focuses on discussing examples of biomaterials in noncellular, artificial cellular, cellular, and gene-based immunotherapies, as well as their advantages and opportunities to create future options for cancer patients.

Original languageEnglish (US)
Title of host publicationBiomaterials for Cancer Therapeutics
Subtitle of host publicationEvolution and Innovation
Number of pages28
ISBN (Electronic)9780081029831
ISBN (Print)9780081029848
StatePublished - Jan 1 2020
Externally publishedYes


  • adoptive cell therapy
  • artificial cellular immunotherapy
  • bispecific T cell engagers
  • Cancer immunotherapy
  • chimeric antigen receptor T cells
  • cytokines
  • immune checkpoint inhibitors
  • monoclonal antibodies
  • mRNA
  • siRNA

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Biomaterials for cancer immunotherapy'. Together they form a unique fingerprint.

Cite this